^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PD-L1 negative + KRAS G12C

    i
    Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule, KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras 2, C-K-RAS, c-Ki-ras, c-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    29126; 3845
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    over1year
    The impact of PD-L1 expression and co-mutations on outcome of KRAS-driven non-small-cell lung cancer. (ASCO 2023)
    Background: Interest has surged for KRAS mutated (KRASmut) non-small-cell lung cancer (NSCLC) after approval of the covalent KRASG12C inhibitors sotorasib and adagrasib. In PD-L1neg NSCLC, KRASG12Cis associated with better outcome under CHT-IO and longer OS compared to KRASother, especially in the absence of TP53 and KEAP1 co-mutations. KEAP1, but not STK11 mutations are associated with impaired benefit from (CHT-)IO in KRASmut NSCLC. Treatment of KRASmut NSCLC after chemo-immunotherapy represents an unmet medical need.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    PD-L1 expression • TP53 mutation • KRAS mutation • TP53 wild-type • STK11 mutation • KEAP1 mutation • PD-L1 negative + KRAS G12C
    |
    Lumakras (sotorasib) • Krazati (adagrasib)